Pregnancy Outcomes and Maternal Insulin Sensitivity
Key facts
- Who runs it
- University Medical Center Groningen
- Where
- Netherlands2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 30 people enrolled
- Started
- 6 Feb 2020
- Ended
- 8 Jul 2024
- Type of study
- Observational
- Treatments tested
- meal tolerance test
- Record updated
- 30 March 2025
- Why it stopped
- slow recruitment, reached sufficient recruitment numbers for exploratory analysis
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Healthy singleton pregnant women (10-12 weeks of gestation)
- BMI ≥25 kg/m2
- FPG ≤7.0 mmol/l
- Dutch or English speaking
- Written informed consent
Who cannot take part
- Participation in any other studies involving the investigation of medication or nutritional products or severe illness or antibiotic use in the two weeks prior to entry into the study
- HIV/Hepatitis
- Known allergies or intolerances for one or more nutritional ingredients in the MTT
- Serious health complications (Hypertension, Hyperlipidemia, Asthma, Haemochromatosis) or medication use that influence the glucose metabolism or fetal growth (e.g. corticosteroids)
- pre-existing Diabetes type 1 and 2 defined as FPG ≥7.0 mmol/l or use of diabetes medication
- Multiple pregnancy
- Expectation of non-compliance to the study protocol, among others, a fear of needles
- Psychological dysfunctions
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The PROMIS study will focus on maternal insulin sensitivity thourghout pregnancy and postpartum in a moderate to high risk population (BMI ≥25 kg/m2) in developing adverse pregnancy outcomes. Next to the OGTT, the meal tolerance test (MTT) will be used as a tool for metabolic testing.
Read full original descriptionShow less
The investigators hypothesize that (early) pregnancy assessment of maternal glucose-insulin metabolism with a MTT in a moderate to high risk group identify more mothers at risk for adverse pregnancy outcomes compared with standard OGTT testing at 24-28 weeks.
The group in the trial
- Healthy women pregnant of singleton with a BMI ≥25 kg/m2
Healthy women pregnant of singleton with a BMI ≥25 kg/m2 will be followed from 12 weeks of gestation till 6 months postpartum. Neonates will be followed from birth up to 6 months of age.
Treatment: meal tolerance test
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Record updated
- 30 March 2025